Tech Company Financing Transactions
Tevard Biosciences Funding Round
Tevard Biosciences, operating out of Boston, secured investment capital from CureDuchenne Ventures.
Transaction Overview
Company Name
Announced On
5/22/2026
Transaction Type
Amount
Unknown
Round
Undisclosed
Investors
CureDuchenne Ventures (Debra Miller)
Proceeds Purpose
The investment will support the advancement of the company's suppressor tRNA (suptRNA) therapy platform for Duchenne muscular dystrophy caused by nonsense mutations.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Lilly Gateway Labs, 15 Necco St
Boston, MA 02210
USA
Boston, MA 02210
USA
Phone
Undisclosed
Website
Email Address
Overview
Pioneering tRNA therapeutics to modulate mRNA function and cure a broad range of genetic diseases. At Tevard, we continue to push our technology forward to find cures for all inherited human diseases caused by nonsense mutations that affect millions of people worldwide.?
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Daniel Fischer
Chief Financial Officer
Dan Lazzari
Chief Scientific Officer
Elisabeth Gardiner
VP - Operations
Paul Kaplan
VP - R & D
Peter Eimon
Browse more venture capital transactions:
Prev: 5/22/2026: REPS venture capital transaction
Next: 5/22/2026: Starlab Space venture capital transaction
Share this article
News on VC Transactions
We report on every notable VC transaction. All VC database entries reported here are sourced from company press releases and news coverage. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs